MedTrace Logo

PD-L1 Expression in Advanced Osteosarcoma

NCT03582527 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2018-08-01

No results posted yet for this study

Summary

The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment. The aim of this study is to detect the expression of PD-1 on advaced osteosarcoma patient who might use these antibodies for treatment. All those specimen should be taken by pathologist and confirmed with high tumor cellularity.

Conditions

  • Progression
  • Survival

Interventions

OTHER

all study participants

patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-12-31
Completion
2020-02-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03582527 on ClinicalTrials.gov